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Background: The absent in melanoma 2 (AIM2), a cytosolic dsDNA inflammasome, can be activated by viral DNA
to trigger caspase-1. Its role in immunopathology of chronic hepatitis B and C virus (HBV, HCV) infection is still
largely unclear. In this study, the expression AIM2, and its downstream cytokines, caspase-1, IL-18 and IL-1β, in liver
tissue of patients with chronic hepatitis B and C (CHB, CHC) were investigated.
Methods: A total of 70 patients diagnosed with chronic hepatitis were enrolled, including 47 patients with CHB
and 23 patients with CHC. A liver biopsy was taken from each patient, and immunohistochemistry was used to
detect the expression of AIM2 and inflammatory factors caspase-1, IL-18, and IL-1β in the biopsy specimens. The
relationship between AIM2 expression and these inflammatory factors was analyzed.
Results: The expression of AIM2 in CHB patients (89.4 %) was significantly higher than in CHC patients (8.7 %), and
among the CHB patients, the expression of AIM2 was significantly higher in the high HBV replication group (HBV
DNA ≥ 1 × 105copies/mL) than in the low HBV replication group (HBV DNA < 1 × 105copies/mL). The expression of
AIM2 was also correlated with HBV-associated inflammatory activity in CHB patients statistically. Additionally, AIM2
levels were positively correlated with the expression of caspase-1, IL-1β and IL-18 in CHB patients, which implied
that the AIM2 expression is directly correlated with the inflammatory activity associated with CHB.
Conclusions: AIM2 upregulation may be a component of HBV immunopathology. The underlying mechanism and
possible signal pathway warrant further study.Introduction
Chronic hepatitis B virus (HBV) infection is a major clin-
ical problem worldwide. The adverse outcomes caused by
chronic HBV infection include cirrhosis, hepatic decom-
position and hepatocellular carcinoma (HCC) [1]. In
addition to the assumption that chronic liver injury is
caused by the inflammatory processes initiated by host
immunity when eliminating the virus, the pathological
mechanisms underlying the progression of chronic hepa-
titis B(CHB) are not well understood. Current research is
focused on the relationship between the adaptive immune* Correspondence: crbdwj@126.com
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there are relatively few studies that have targeted the rela-
tionship between innate immunity and CHB.
The innate immune system is the first line of defense
against invading microbes and is activated by the engage-
ment of germline-encoded pattern-recognition receptors
(PRRs) [2]. PRRs recognize specific components of mi-
crobes and initiate the inflammatory pathway to prevent
microbial invasion [2]. A major aspect of the inflammatory
pathway is the activation of the inflammasome. The
inflammasome is a multi-protein complex that can acti-
vate caspase-1, resulting in the cleavage and maturation of
the pro-inflammatory cytokines interleukin-1β (IL-1β) and
IL-18 [2]. Absent in melanoma 2 (AIM2) is one of the key
genes orchestrating the formation of the inflammasome.
AIM2 is a member of the IFI20X-IFI16 protein family
[3] and can bind to double-stranded DNA and to thedistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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protein), which contains a caspase activation and recruit-
ment domain. This complex then activates caspase-1 and
leads to the formation of mature IL-1β and IL-18 [4]. Al-
though AIM2 is known to be involved in the host defense
against microbial invasion, its role in regulating the im-
mune response to viruses, such as HBV, has not been well
understood. A few studies have investigated caspase-1,
IL-1β and IL-18 expression in patients with CHB, CHC,
and other viral hepatitis [5–8]. HBV is a double-stranded
DNA virus (HBV DNA) which has undergone replication
in the nucleus of liver cells and re-entered the cytoplasm
to finish packaging [9]. However, the expression of AIM2
and its relationship with liver inflammation in liver tissue
in patients with CHB and CHC is still unclear.
In this study, we investigated the expression of AIM2
caspase-1, IL-1β, and IL-18 in liver tissue in patients
with CHB or CHC.
Patients and methods
Patients
Subjects who fulfilled the following criteria were recruited
into the groups: (1) age between 18 and 60 years old; (2)
CHB or CHC without HAV, HDV, HEV or HIV co-infection;
(3) without a history or current evidence of cancer; (4)
alpha-fetoprotein (AFP) < 13.6 ng/mL; (5) without nucleo-
tide/nucleosides or interferon treatment history; (6) with-
out having used any heap-protective drugs or immune
agents in the past 3 months; (7) without evidence of auto-
immune diseases; and (8) agreement to liver biopsy. 47 pa-
tients with CHB and 23 patients with CHC were recruited
between September 2009 and July 2011 at Jinan Infectious
Disease Hospital and Qianfoshan Hospital of Shandong
University, Shandong. All subjects received liver puncture
biopsy under ultrasound guidance to attain hepatic tissue
of no less than 2 cm in length for diagnosis and subsequent
research. The study was approved by the ethics committee
of Jinan Infectious Disease Hospital, and written informed
consent for participation was obtained from each participator.
Diagnosis of CHB and CHC
The diagnostic criteria for CHB were in accordance with
the Asian-Pacific Consensus Statement on the Manage-
ment of Chronic Hepatitis B [1, 10, 11].
The criteria for diagnosis of CHC followed the 2014
World Health Organization Guidelines for the screening,
care and treatment of persons with hepatitis C infection [6].
Immunohistochemistry and scoring
All liver tissue specimens were first fixed in 10 % forma-
lin, and then the tissue was cut, dehydrated, dipped in
wax, embedded and sectioned. These sections were then
placed on slides, baked, placed into xylene, cleared of
the wax, rehydrated using graded ethanol and immersedin 0.3 % hydrogen peroxide for 5 min to reduce non-
specific background staining caused by endogenous per-
oxidase. The slides were then washed with PBS buffer
three times for 5 min each, placed in citrate buffer solu-
tion at a pH of 6.0 and then into a high temperature
pressure pot to recover the tissue antigen. After being
heated, the slides were cooled and restored at room
temperature, washed three more times in PBS buffer and
incubated with AIM2, IL-18 and IL-1β primary anti-
bodies (rabbit anti-human monoclonal antibody, Abcam,
England) and caspase-1primary antibody (mouse anti-
human monoclonal antibody, Santa Cruz Biotechnology
Inc., USA). The slides were then placed in a 4 °C
refrigerator overnight. The next day, the slides were
washed with PBS buffer three times, each time lasting
longer than 5 min, then incubated with the secondary
antibody PV-9000 (universal antibody) at 37 °C for
10 min, washed with PBS buffer, and DAB staining was
applied. The stain was terminated using running water,
then the slides were washed with hydrochloric acid alco-
hol for differentiation. Lastly, the slides were washed
with distilled water, cleared with xylene and mounted.
Appearance of a tan stain in the cytoplasm signaled
positive expression of the protein. Scores were assigned
based on percentage of positive cells and intensity of
staining. Negative (−) was defined as no cells stained;
mildly positive (+): 1–30 % of cells stained; moderately
positive (++): 30–60 % of cells stained; and strongly
positive (+++): more than 60 % of cells stained. Scores
for stain intensity and percent of positivity were then
added together, and a negative (−) was assigned for
scores 0, mildly positive (+) for scores between 1 and 3,
moderately positive (++) for scores between 4 and 6, and
strongly positive (+++) for scores greater than 7.
Histological assessment and quantification of fibrosis
Hepatic biopsies were obtained using 16 gauge disposable
needles (D-78187, Gesingen, Germany). Liver specimens
(median 22 mm, interquartile range [IQR] 20–23 mm)
were stained with hematoxylin and eosin. Fibrosis staging
(S) and inflammatory activity (G) were scored according
to Precautionary and Curative Measures of Hepatitis Virus
(PCMHV) [7]. For means of classification, the level of
fibrosis in tissue specimens was divided into five stages,
S0–S4: S0, no fibrosis; S1, portal fibrosis without septa but
with minimal fibrosis of hepatic lobules; S2, periportal
fibrosis with few septa and moderate fibrosis of hepatic
lobules; S3, septal fibrosis with many septa and structural
distortion of hepatic lobules; and S4, cirrhosis. Inflamma-
tory activity was similarly divided into five grades, G0–G4:
G0, no histologic necroinflammation; G1, portal inflam-
matory activity; G2, minimal patch necrosis; G3, moderate
patch necrosis; and G4, severe patch necrosis. In accord-
ance with the PCMVH, we defined significant fibrosis as
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fibrosis as having a score of three or greater (S3, 4).
Statistical analysis
The SPSS program (version 17.0) was used for analysis.
Measurement data was described as mean ± standard de-
viation. Background factors were compared using the
Student’s t-test (numerical data) or the Chi-square test
(categorical data). Spearman’s two-tailed test was used for
correlation analysis, and differences were regarded as sig-
nificant if the p value was less than 0.05 on either side.
Results
Expression of AIM2 was significantly increased and highly
correlated with HBV load in CHB patients
We compared the expression of AIM2 in hepatic biopsies
from 47 CHB patients and 23 CHC patients to determine
whether AIM2 expression was correlated with HBV infec-
tion. Figure 1 shows the expression status of AIM2 ran-
ging from negative (−) to strong positive (+++), as
detected with immunohistochemistry, and suggests that
AIM2 is exclusively expressed in the hepatic cellular cyto-
plasm, which is consistent with previous research [4]. To
assess whether the observed results were indeed compar-
able, we also analyzed other clinical characteristics of both
groups of patients (Table 1). No significant differences
were observed between CHB patients and CHC patients
in regard to their age (p = 0.075), gender (p = 0.81), liverFig. 1 Immunostaining of AIM2 in the hepatocyte cytoplasm of CHB. a Ne
positive of AIM2. d Strong positive of AIM2. (Magnification of 400×)function (ALT, p = 0.292; AST, p = 0.241; TB, p = 0.24;
albumin, p = 0.165) or routine blood test (WBC, p = 0.381;
PLT, p = 0.366). Statistical analysis revealed that the
positive expression rate of AIM2 in CHB patients was
significantly higher than that in CHC patients (89.4 vs.
8.7 %, p < 0.00). To further clarify the factors affecting
the expression of AIM2 in CHB patients, we checked
the potential influence of age, gender, liver function,
and HBV DNA level on the expression of AIM2.
As summarized in Table 2, the results showed that
AIM2 expression was not affected by age (p = 0.178) or
gender (p = 0.148). The results also showed that AIM2
expression was significantly correlated with the level of
ALT (p = 0.03) but not AST (p = 0.378). As for HBV status,
we found that the expression of AIM2 was significantly
higher in patients with high viral load (HBV-DNA ≥ 1 ×
105copies/mL) than in patients with low viral load (HBV-
DNA < 1 × 105 copies/mL) (p < 0.01); However, the ex-
pression of AIM2 was not related to hepatitis B e antigen
(e-Ag) status (p = 0.825). These results suggest that the
expression of AIM2 may be dependent on HBV load and
may play certain roles in CHB.
Expression of AIM2 was correlated with inflammatory
activity in CHB
Inflammatory activity and fibrosis staging are important
pathological characteristics. High inflammatory activity
indicates the severity of hepatic damage, and fibrosisgative expression of AIM2. b Weak positive of AIM2. c Moderate
Table 1 Clinical characteristics and expression of AIM2 between
CHB group and CHC group
CHB CHC P value
n = 47 n = 23
Age (y) 38.2 ± 9.0 37.8 ± 9.6 0.750
Male, n (%) 30(63.8) 14(60.9) 0.810
ALT (IU/L) 64.1 ± 40.0 55.5 ± 31.9 0.292
AST (IU/L) 63.8 ± 25.0 58.4 ± 37.7 0.241
TB (μmol/mL) 18.6 ± 7.7 26.7 ± 9.7 0.240
ALB (g/L) 38.6 ± 11.9 39.8 ± 6.2 0.165
PTA (%) 85.7 ± 10.9 86.3 ± 12.4 0.722
WBC (109/L) 6.4 ± 1.8 6.6 ± 2.0 0.381
PLT (109/L) 137.7 ± 51.7 176.3 ± 55.6 0.366
AIM2, n (%) 42(89.4) 2 (8.7) 0.000
AIM2 absent in melanoma, CHB chronic hepatitis B, CHC chronic hepatitis C,
ALT alanine transaminase, AST aspartate aminotransferase, TB total Bilirubin,
ALB albumin, PTA prothrombin activity, WBC white blood cell, PLT platelet
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of inflammation to cirrhosis. To reveal what role AIM2
plays in CHB patient liver damage, we analyzed the cor-
relation between AIM2 expression and fibrosis and in-
flammation. The results showed that the expression of
AIM2 was highly correlated with the degree of inflam-
mation (p = 0.007) but not with the degree of fibrosis
(p = 0.101) (Table 3).
We further analyzed the correlation between AIM2
and caspase-1, IL-1β and IL-18 expression in CHB pa-
tients (Fig. 2). Statistical analysis revealed that the levelTable 2 Correlation between AIM2, clinical characteristics, and lab fi
AIM2
n − +
Male 30 1(3.3 %) 8(26.7 %)
Age(years)
20–40 30 3(10.0 %) 9(30.0 %)
40–60 17 2(11.8 %) 1(5.9 %)
ALT
ULN-2ULN 32 5(15.6 %) 7(21.9 %)
2ULN-5ULN 15 0(0 %) 3(20.0 %)
AST
ULN-2ULN 38 4(10.5 %) 9(23.7 %)
2ULN-5ULN 9 1(11.1 %) 1(11.1 %)
eAg
Positive 26 3(11.5 %) 5(19.2 %)
Negative 21 2(9.5 %) 5(23.8 %)
HBV DNA
≥ 105copies/mL 25 0(0 %) 0(0 %)
< 105copies/mL 22 5(20.0 %) 10(40.0 %)
CHB chronic hepatitis B, ALT Alanine aminotransferase, AST Aspartate aminotransferof AIM2 was positively correlated with the level of
caspase-1 (rs = 0.738, p < 0.01), IL-1β (rs = 0.527, p < 0.01)
and IL-18 (rs = 0.642, p < 0.01) (Table 4). Both IL-1β and
IL-18, important factors contributing to the develop-
ment of chronic hepatocellular inflammation. Figure 2 il-
lustrates the expression of AIM2, caspase-1, IL-1β and
IL-18 in these patients. These results suggested that the
expression of AIM2 was specifically correlated with in-
flammation in CHB and that elevation of AIM2
corresponding to HBV infection or replication may con-
tribute to the inflammatory damage associated with the
development of CHB.
Discussion
AIM2 was first reported in malignant melanoma cell
lines and was thought to act as a tumor suppressor by
repressing NF-κB transcriptional activity [2]. Recent
research has demonstrated that AIM2 plays an import-
ant role in the innate immune response through sensing
potentially dangerous cytoplasmic DNA and inducing
the formation of the ASC inflammasome, which then
induces activation of caspase-1 and release of mature IL-
1β and IL-18 [4]. As a receptor for cytoplasmic DNA,
AIM2 can be activated by poly (dA:dT), plasmidic DNA
and DNA from the bacterium L. monocytogenes, and
even synthetic dsDNA [12]. Notably, dsDNA vaccinia
virus has been shown to activate AIM2 [13].
Previous research indicated that AIM2 is highly
expressed in the small intestine, spleen, peripheral white
blood cells and testis [14]. In this study, we found thatndings in CHB group
++ +++ x2 p
10(33.3 %) 11(36.7 %) 5.351 0.148
4.918 0.178
7(23.3 %) 11(36.7 %)
8(47.0 %) 6(35.3 %)
39.987 0.030
9(28.1 %) 11(34.4 %)
6(40.0 %) 6(40.0 %)
36.487 0.378
12(31.6 %) 13(34.2 %)
3(33.3 %) 4(44.4 %)
0.049 0.825
9(34.6 %) 9(34.6 %)
6(28.6 %) 8(38.1 %)
25.96 <0.001
10(40.0 %) 15(60.0 %)
5(20.0 %) 2(8.0 %)
ase, ULN upper limits of normal
Table 3 Correlation between expression of AIM2 and inflammatory activity and fibrosis staging in CHB
AIM2 G S
0 1 2 3 4 0 1 2 3 4
n = 0 n = 9 n = 14 n = 13 n = 11 n = 0 n = 13 n = 6 n = 8 n = 20
− 0 1 3 1 0 0 1 2 0 2
+ 0 6 1 0 3 0 6 0 0 4
++ 0 2 3 5 5 0 4 1 3 7
+++ 0 0 7 7 3 0 2 3 5 7
X2 22.707 14.636
P 0.007 0.101
G Inflammatory activity, S Fibrosis staging
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AIM2 is exclusively expressed in hepatic cytoplasm. Fur-
thermore, we found that the positive expression rate of
AIM2 in CHB group was significantly higher than that
in CHC control group. As neither clinical characteristics
nor lab findings were statistically different between the
two groups, this suggested that there is indeed a rela-
tionship between chronic HBV infection and AIM2
elevation.
In the CHB group, expression of AIM2 did not differ
between e-Ag positive and e-Ag negative patients. More-
over, our results indicated that the expression of AIM2
in the high replication group (HBV DNA ≥ 1 × 105cop-
ies/mL) was significantly higher than that in the lowFig. 2 The strong expression of AIM2, caspase-1, IL-1β, and IL-18 in liver tissu
c Strong expression of IL-1β. d Strong expression of IL-18. The four sections wreplication group (HBV DNA < 1 × 105copies/mL), sug-
gesting that high HBV load led to the increase in AIM2
expression. The relationship between high HBV load
and progression of CHB infection has been tested show-
ing an increasing incidence of HCC with high viral load
[15–19]. While the function of AIM2 in HCC tumori-
genesis is unclear, AIM2 has widely been believed to act
as a tumor suppressor in a variety of cancer types via
repressing NF-κB transcriptional activity [20–24]. How-
ever, recent research suggests that AIM2 may also act as
an oncogene in some cancers [25]. Our results suggest
that AIM2 expression may be related to the occurrence
and development of HCC, a noteworthy finding to
which further study should be devoted.e of CHB. a Strong expression of AIM2. b Strong expression of caspase-1.
ere taken from the same CHB patient (Magnification of 400×)
Table 4 Correlation between expression of AIM2 and Caspase-1,
IL-1β and IL-18 in CHB group
AIM2 CHB
Capase-1 IL-1β IL-18
− + ++ +++ − + ++ +++ − + ++ +++
− 5 0 0 0 4 1 0 0 5 0 0 0
+ 6 4 0 0 5 3 0 1 3 6 0 1
++ 0 4 9 2 3 5 6 1 1 7 6 1
+++ 1 0 2 14 1 5 7 4 1 3 7 6
rs 0.738 0.527 0.642
p < 0.01 < 0.01 < 0.01
AIM2 absent in melanom2, CHB chronic hepatitis B, IL-1β interleukin-1β,
IL-18 interleukin-18
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and inflammatory activity in patients with CHB. High
levels of AIM2 were present in patient tissue specimens
with a severe inflammatory grade, and low levels of
AIM2 were found in mild cases, which suggest a rela-
tionship between the expression of AIM2 and liver in-
flammatory injury. Liver fibrosis is the accumulation of
chronic inflammation in the liver. The observation that
AIM2 is differentially expressed in regards to liver in-
flammatory grade versus stage of fibrosis suggests that
AIM2 is closely associated with inflammation, not fi-
brotic development. Expression of AIM2 in groups with
various levels of ALT and inflammatory activity was
shown to be statistically different. ALT was regarded as
the most important liver function index, reflecting hep-
atic inflammation for characteristics primarily in the
hepatic cell; however, the degree of accuracy in apprais-
ing liver inflammatory activity still plays a small role in
histodiagnosis. Because ALT values are easily affected by
circumstance and condition, mildly elevated ALT might
not truly translate to mild hepatic tissue damage [26].
Hepatic tissue tests are still regarded as the standard in
appraising hepatic inflammatory damage. The relationship
between the expression of AIM2 and hepatic tissue in-
flammatory grade is in fact stronger using these methods.
Our results showed that the expression of AIM2 is
positively correlated with IL-1β and IL-18 expression in
CHB patients and not correlated in the control fatty liver
disease patient group. This might suggest that the mech-
anism of releasing IL-1β and IL-18 during CHB and
CHC is different, although chronic inflammation was
observed in both groups. The difference in correlation
between AIM2 and caspse-1, IL-1β and IL-18 in CHB
and CHC implies that the underlying cause for hepatic
damage may be different between CHB and CHC. Dur-
ing the innate immune response to invading microbes,
activated AIM2 may bind to asymptomatic carriers of
hepatitis B virus (ASC), inducing activation of caspase-1
and releasing IL-1β and IL-18 [4]. Such a model of signaltransfer was shown in our study. Within the CHB
group, the expression level of AIM2 was positively cor-
related with the level of caspase-1, and the level of
caspase-1 was positively correlated with levels of IL-
1βand IL-18, further suggesting that this inflammation
signal transfer pathway is related to AIM2 levels in
CHB infections. IL-1β and IL-18 are both important
intracellular cytokines belonging to the IL-1 superfam-
ily [23]. Each binds to receptors and activates the
downstream NF-ĸB signaling pathway, releasing inflam-
matory factors. Indeed, IL-1β and IL-18 release is
known to cause tissue damage [24]. Collectively, the
binding of HBV DNA to AIM2 may lead to the activa-
tion of caspase-1, inducing release ofIL-1β and IL-18,
which in turn may play an important role in the patho-
genesis of CHB.
Conclusions
The present study showed the expression of AIM2 is cor-
related with increased inflammation in patients with
chronic hepatitis B. AIM2 upregulation may be a compo-
nent of HBV immunopathology. The underlying mechan-
ism and possible signal pathway warrant further study.
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